Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very ...

Cogent Biosciences, Inc. stock soars after bezuclastinib's strong Phase 3 results in GIST. Click for my updated look at COGT ...

On Monday, 10 November 2025, the healthcare world was abuzz as two pharmaceutical giants, Pfizer and Novo Nordisk, fiercely ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

Pfizer not only beat expectations last quarter, but also boosted its guidance.

Pfizer acquires biotech firm Metsera for $10 billion to re-enter the obesity treatment market. This move positions Pfizer ...

Launching next year, the new CMS Innovation Center initiative—known as the GENEROUS Model—aims to align Medicaid drug prices ...

Pfizer Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

Pfizer has fended off Nova Nordisk for control of the next-gen weight-loss drug developer Metsera. Meanwhile, Resmed watches ...

U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera , capping a fierce biotech bidding ...

The US drug giant beat Novo Nordisk in the $10 bln battle for biotech Metsera with the help of the Federal Trade Commission.

Shares of Novo Nordisk increased after the company withdrew its bid for U.S. weight loss drug maker Metsera, allowing Pfizer to secure a $10 billion deal. This move grants Pfizer entry into the ...